ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613
November 11, 2020Rafael Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for CPI-613® (devimistat) for the treatment of soft tissue sarcoma. -
Cancer drug with accelerated approval fails Phase III trial
January 24, 2019Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone… -
Tazemetostat Granted Orphan Drug Designation for the Treatment of Soft Tissue Sarcoma
June 22, 2017Epizyme announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation to tazemetostat, the company’s first-in-class EZH2 inhibitor, for the treatment of patients with soft tissue sarcoma (STS).
Pharma Sources Insight January 2025
